M&A activity is going beyond big pharma acquisitions with Supernus Pharmaceuticals and Indivior Pharmaceuticals reaching a stock deal that the companies call a merger of equals. The combined company’s portfolio will have 11 commercialized products in addiction, attention-deficit hyperactivity disorder, depression, and Parkinson’s disease.
The post Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company appeared first on MedCity News.
Labcorp Paying Out $35M in Settlement: Who’s Eligible – Newsweek
Labcorp Paying Out $35M in Settlement: Who’s Eligible Newsweek
